Quantcast

Synovial Sarcoma - Online Support Group

Nivolumab and Ipilimumab Phase 2 Trial


#1

New York Presbyterian released the following update about a phase 2 trial combining Nivolumab (a.k.a Opdivo, anti-PD-1) and Ipilimumab (a.k.a Yervoy, anti-CTLA-4):
http://www.nyp.org/news/Backed-by-Immunotherapy-New-Approach-to-Rare-Cancer-Effective
Results were presented at ASCO2017:
http://abstracts.asco.org/199/AbstView_199_184079.html
Apparently, there was no response observed in synovial sarcoma patients (only a few patients participated):